Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
BM (Hons) FRCP DM
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
Double-negative neuromyelitis optica spectrum disorder.
Wu Y. et al, (2023), Mult Scler, 29, 1353 - 1362
The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
Berhanu D. et al, (2023), Mult Scler
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B. et al, (2023), Ann Neurol
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F. et al, (2023), Neurol Neuroimmunol Neuroinflamm, 10
Care Recommendations for the Investigation and Management of Children With Skeletal Muscle Channelopathies.
Matthews E. et al, (2023), Pediatr Neurol, 145, 102 - 111